Febre amarela

Referências

Principais artigos

Monath TP. Yellow fever: an update. Lancet Infect Dis. 2001;1:11-20. Resumo

World Health Organization. Vaccines and vaccination against yellow fever. WHO position paper - June 2013. Wkly Epidemiol Rec. 2013;88:269-284.Texto completo  Resumo

Staples JE, Bocchini JA Jr, Rubin L; Centers for Disease Control and Prevention (CDC). Yellow fever vaccine booster doses: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:647-650.Texto completo  Resumo

Gotuzzo E, Yactayo S, Córdova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2013;89:434-444. Resumo

Pan American Health Organization; World Health Organization. Laboratory diagnosis of yellow fever virus infection. September 2018 [internet publication].Texto completo

Artigos de referência

1. Barnett ED. Yellow fever: epidemiology and prevention. Clin Infect Dis. 2007;44:850-856.Texto completo  Resumo

2. Monath TP. Yellow fever: an update. Lancet Infect Dis. 2001;1:11-20. Resumo

3. World Health Organization. Vaccines and vaccination against yellow fever. WHO position paper - June 2013. Wkly Epidemiol Rec. 2013;88:269-284.Texto completo  Resumo

4. World Health Organization. Disease outbreak news. Yellow fever - Mali. December 2019 [internet publication].Texto completo

5. World Health Organization. Disease outbreak news. Yellow fever - Nigeria. December 2017 [internet publication].Texto completo

6. World Health Organization. Disease outbreak news. Yellow fever - Nigeria. December 2019 [internet publication].Texto completo

7. World Health Organization. Winning the war against yellow fever. November 2016 [internet publication].Texto completo

8. World Health Organization. Weekly epidemiological record. Yellow fever in Africa and the Americas, 2017. August 2018 [internet publication].Texto completo

9. Wilder-Smith A, Monath TP. Responding to the threat of urban yellow fever outbreaks. Lancet Infect Dis. 2017;17:248-250.Texto completo  Resumo

10. Centers for Disease Control and Prevention (CDC). Health information for international travel (Yellow Book). Chapter 4: travel-related infectious diseases, Yellow fever. August 2019 [internet publication].Texto completo

11. World Health Organization. Yellow fever in the WHO African and American Regions, 2010. Wkly Epidemiol Rec. 2011;86:370-376.Texto completo  Resumo

12. World Health Organization: Global Response and Alert (GAR). Yellow fever: a current threat. 2017 [internet publication].Texto completo

13. Vasconcelos PF, Costa ZG, Travassos da Rosa ES, et al. Epidemic of jungle yellow fever in Brazil, 2000: implications of climatic alterations in disease spread. J Med Virol. 2001;65:598-604. Resumo

14. Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA. 1997;278:399-411. Resumo

15. Advisory Committee on Immunization Practices (ACIP). General recommendations on immunization - recommendations of the ACIP. MMWR Recomm Rep. 2011;60:1-64.Texto completo  Resumo

16. Centers of Disease Control and Prevention. Fatal yellow fever in a traveler returning from Amazonas, Brazil, 2002. MMWR Morb Mortal Wkly Rep. 2002;51:324-325.Texto completo  Resumo

17. Cornet JP, Huard M, Camicas JL, et al. Experimental transmission of the yellow fever virus by the tick Amblyomma variegatum (F.). Bull Soc Pathol Exot Filiales. 1982;75:136-140. Resumo

18. Staples JE, Bocchini JA Jr, Rubin L; Centers for Disease Control and Prevention (CDC). Yellow fever vaccine booster doses: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:647-650.Texto completo  Resumo

19. World Health Organization. Updates on yellow fever vaccination recommendations for international travelers related to the current situation in Brazil. May 2018 [internet publication].Texto completo

20. Gotuzzo E, Yactayo S, Córdova E. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2013;89:434-444. Resumo

21. Grobusch MP, Goorhuis A, Wieten RW, et al. Yellow fever revaccination guidelines change - a decision too feverish? Clin Microbiol Infect. 2013;19:885-886. Resumo

22. World Health Organization Department of Immunization, Vaccines and Biologicals. Fractional dose yellow fever vaccine as a dose-sparing option for outbreak response. July 2016 [internet publication].Texto completo

23. Casey RM, Harris JB, Ahuka-Mundeke S, et al. Immunogenicity of fractional-dose vaccine during a yellow fever outbreak - final report. N Engl J Med. 2019 Aug 1;381(5):444-454.Texto completo  Resumo

24. Roukens AHE, van Halem K, de Visser AW, et al. Long-term protection after fractional-dose yellow fever vaccination: follow-up study of a randomized, controlled, noninferiority trial. Ann Intern Med. 2018 Nov 27 [Epub ahead of print]. Resumo

25. Thomas RE, Lorenzetti DL, Spragins W, et al. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: Systematic review. Vaccine. 2011;29:4544-4555. Resumo

26. Farez MF, Correale J. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Arch Neurol. 2011;68:1267-1271. Resumo

27. Traiber C, Coelho-Amaral P, Ritter VR, et al. Infant meningoencephalitis caused by yellow fever vaccine virus transmitted via breastmilk. J Pediatr (Rio J). 2011;87:269-272. Resumo

28. Barte H, Horvath TH, Rutherford GW. Yellow fever vaccine for patients with HIV infection. Cochrane Database Syst Rev. 2014;(1):CD010929.Texto completo  Resumo

29. Nascimento Silva JR, Camacho LA, Siqueira MM, et al; Collaborative Group for the Study of Yellow Fever Vaccines. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine. 2011;29:6327-6334. Resumo

30. Medicines and Healthcare products Regulatory Agency. Yellow fever vaccine: stronger precautions in people with weakened immunity and in those aged 60 years or older. November 2019 [internet publication].Texto completo

31. Mirzaian E, Durham MJ, Hess K, et al. Mosquito-borne illnesses in travelers: a review of risk and prevention. Pharmacotherapy. 2010;30:1031-1043. Resumo

32. Pan American Health Organization; World Health Organization. Laboratory diagnosis of yellow fever virus infection. September 2018 [internet publication].Texto completo

33. Drosten C, Göttig S, Schilling S, et al. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol. 2002;40:2323-2330.Texto completo  Resumo

34. Domingo C, Patel P, Yillah J, et al. Advanced yellow fever virus genome detection in point-of-care facilities and reference laboratories. J Clin Microbiol. 2012;50:4054-4060. Resumo

35. World Health Organization. CDC and WHO launch trial version of a new ELISA: a kit, simpler and faster to perform. July 2018 [internet publication].

36. World Health Organization.Yellow fever: case definitions for public health surveillance. May 2015 [internet publication].Texto completo

37. Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System (NNDSS): yellow fever - 1997 case definition. 1997 [internet publication].Texto completo

38. Monath TP. Treatment of yellow fever. Antiviral Res. 2008;78:116-124. Resumo

39. Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis. 1989;11(suppl 4):S750-S761. Resumo

40. Arroyo JI, Apperson SA, Cropp CB, et al. Effect of human gamma interferon on yellow fever virus infection. Am J Trop Med Hyg. 1988;38:647-650. Resumo

41. Julander JG. Experimental therapies for yellow fever. Antiviral Res. 2013;97:169-179. Resumo

42. Centers for Disease Control and Prevention. Adverse events associated with 17D-derived yellow fever vaccination: United States, 2001-2002. MMWR Morb Mortal Wkly Rep. 2002;51:989-993.Texto completo  Resumo

43. Veit O, Niedrig M, Chapuis-Taillard C, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis. 2009;48:659-666. Resumo

44. ter Meulen J, Sakho M, Koulemou K, et al. Activation of the cytokine network and unfavorable outcome in patients with yellow fever. J Infect Dis. 2004;190:1821-1827.Texto completo  Resumo

45. Marianneau P, Georges-Courbot M, Deubel V. Rarity of adverse effects after 17D yellow-fever vaccination. Lancet. 2001;358:84-85. Resumo

46. Borio L, Inglesby T, Peters CJ, et al; Working Group on Civilian Biodefense. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA. 2002;287:2391-2405. Resumo

47. Bossi P, Tegnell A, Baka A, et al. Bichat guidelines for the clinical management of haemorrhagic fever viruses and bioterrorism-related haemorrhagic fever viruses. Euro Surveill. 2004;9:E11-E12.Texto completo  Resumo

O uso deste conteúdo está sujeito ao nosso aviso legal